Incidence of Cisplatin Induced Ototoxicity in Adults with Head and Neck Cancer. (12th November 2015)

• Record Type: Journal Article
• Authors: Greene, Joshua B.; Standring, Robert; Siddiqui, Farzan; Ahsan, Syed F.
• Other Names: Mercante Giuseppe Academic Editor.
• Is Part Of: Advances in otolaryngology. Volume 2015(2015)
• Publication Date: 2015-11-12
• Subjects: Otolaryngology -- Periodicals; Otolaryngology; Otolaryngology; Periodicals; 617.51
• DOI: 10.1155/2015/245613
• Languages: English
• ISSNs: 2356-6833

Abstract

Abstract : Objective . To elucidate the incidence of cisplatin induced ototoxicity in adult patients, with a focus on an adult population. Study Design . IRB approved retrospective study. Methods . The charts of patients who underwent cisplatin therapy from 1995 to present were reviewed. Inclusion criteria were (1) cisplatin as the primary chemotherapeutic agent and (2) hearing evaluation performed prior to and after treatment. Audiometric thresholds were measured by presenting pure-tone stimuli at 0.25 to 10.0 kHz. Criteria for hearing loss were based on the Chang criteria. Cochlear radiation doses were also calculated in patients with primary tumors in their head and neck or brain. Results . There were 1565 patients that had undergone therapy with cisplatin from 1995 to 2014, which 30 met inclusion criteria. Eight were patients treated for head and neck or brain cancer. Evaluation with ANOVA testing identified statistically significant decline in audiometric scores for WRS and pure tone frequencies 500, 2000, 4000, 6000, and 8000 Hz in the right ear. Overall, hearing loss was noted with 63% incidence and in patients who received radiation to their cochlea and cisplatin. Conclusion . The incidence of cisplatin induced ototoxicity was significant and even more prevalent in those patients receiving both cisplatin and radiation to their cochlea.